Physician profile
David L Nerness
NPI 1205870771
$1,407.72
in general payments reported to CMS, 2019-2025
23 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.49 · 2023: $268 · 2024: $744 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.45 | 2023-2025 | |
| Novo Nordisk INC | $219.75 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $111.65 | 2023-2025 | |
| Lilly USA, LLC | $99.73 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $90.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.30 | 2025 | Caplyta |
| Mylan Specialty L.P. | $45.91 | 2024 | Yupelri |
| Dexcom, INC. | $45.20 | 2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $40.22 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.99 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $36.87 | 2023-2024 | Verquvo, Belsomra, Gardasil |
| Otsuka America Pharmaceutical, INC. | $36.13 | 2023-2024 | Rexulti |
| Ardelyx, INC. | $35.23 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $34.62 | 2023-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $33.94 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $32.75 | 2024-2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $32.05 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $17.46 | 2024 | Rexulti |
| Antares Pharma, INC. | $16.51 | 2024 | Xyosted |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $14.60 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $14.15 | 2024 | Xarelto |
| Pfizer INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nerness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.